Cytarabine (Ara-C) clinical trials

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

This study is testing a new drug, ziftomenib, for a type of blood cancer called AML. It combines ziftomenib with standard treatments for patients who haven't had treatment before, aiming to see if it works better than usual care alone.